All News

Christopher Lis, senior director at JD Power, shared key insights about the report and what the pharmacy landscape currently looks like.

Unicycive Therapeutics secures a US patent for UNI-494, a promising treatment for chronic kidney disease, enhancing its development and partnership potential.

New research uncovers the complex tumor microenvironment in multiple myeloma, revealing unique plasma cell ecosystems that challenge existing treatment approaches.

Plozasiran significantly reduces triglyceride levels and pancreatitis risk in FCS patients, offering hope for effective treatment options.

FDA approves a new liquid formulation of losartan for hypertension treatment, enhancing accessibility for adults and children over 6 years old.

Virtual health care enhances patient experiences, integrates complex data, and ensures medication access through provider-pharmacist collaboration.

Researchers unveil a promising drug combination, arainosine and theobromine, that effectively targets influenza A M2 channels, outperforming existing treatments.

FDA approves semaglutide for treating MASH, offering new hope for affected individuals.

Oncology pharmacists are increasingly shaping patient care.

FDA approves Tonmya, the first new fibromyalgia treatment in 15 years, offering hope for effective pain relief and improved quality of life.

New research highlights abemaciclib and ribociclib as promising treatments for early HR-positive, HER2-negative breast cancer, emphasizing survival benefits and adverse effects.

Combination therapy with tremelimumab and durvalumab significantly improves survival in patients with liver cancer compared with standard sorafenib treatment.

Morgan Cantley, PharmD, BCOP, shares key insights about the HER2-targeting antibody-drug conjugate trastuzumab deruxtecan.

IDSA updated cUTI guidelines for men and women emphasize antibiotic selection, transition to oral therapy, and optimal treatment duration.

Revumenib shows promise in treating NPM1-mutant AML, expanding its role in precision oncology and offering hope for targeted leukemia therapies.

CT-155, an investigational prescription digital therapeutic, was found to improve motivation, sociality, and other negative symptoms in patients with schizophrenia as an adjunct to antipsychotic treatment.

Tenapanor offers a new approach to managing hyperphosphatemia in dialysis patients, balancing effectiveness with pill burden and cost considerations.

New findings highlight environmental impacts on weight management.

Pharmacists optimize biosimilar and 505(b)(2) use through collaboration, education, and integration.

In pharmacy, this model encourages taking responsibility and the open reporting of errors and near-misses without fear of punishment.

Aficamten offers new hope for HCM patients, showing significant clinical benefits and safety in recent trials, enhancing treatment options.

Acalabrutinib shows improved safety and survival rates in chronic lymphocytic leukemia (CLL), reducing risks of mortality and cardiovascular complications.

The designation is supported by promising results from the ongoing phase 1/2 BEACON clinical trial.

Pharmacists explore kratom's potential benefits and risks, emphasizing the need for education on its effects, safety, and patient guidance.

A collaborative care model enhances education and management for patients with chronic kidney disease, improving outcomes and understanding.

Stiff Person Syndrome has unique complexities, necessitating the role of pharmacists in managing its symptoms and treatment options.

Vitamins D and K work together to enhance bone strength and cardiovascular health, ensuring optimal calcium regulation for overall wellness.

Oncology pharmacists can lead value-based care integration under EOM with data-driven strategies.

Scott A. Soefje, PharmD, MBA, BCOP, FCCP, FHOPA, discusses how Medicaid payment changes could impact rural hospitals and local pharmacies, noting the importance of pharmacists staying involved as the situation develops.